WordNet

a soft thin (usually translucent) paper (同)tissue_paper
part of an organism consisting of an aggregate of cells having a similar structure and function
an enzyme liberated from blood platelets that converts prothrombin into thrombin as blood starts to clot (同)thrombokinase, factor_III

PrepTutorEJDIC

〈U〉〈C〉(生物体の)『組織』 / 〈U〉〈C〉『薄織物』 / 〈U〉〈C〉水を吸収する柔らかな薄紙 / 〈C〉カーボンコピー用薄紙 / 〈C〉《a ~》(…を)織り交ぜて作ったもの《+of+名》 / =tissue paper

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 止血の概要 overview of hemostasis
2. 第VIII因子および第IX因子の生物学と正常な機能 biology and normal function of factor viii and factor ix
3. 悪性腫瘍に関連した凝固亢進状態の病因 pathogenesis of the hypercoagulable state associated with malignancy
4. 敗血症に対する治験剤および無効剤 investigational and ineffective therapies for sepsis
5. 胎盤早期剥離：臨床的特徴および診断 placental abruption clinical features and diagnosis

Honaker J, Brockopp D, Moe K.Author information Jeremy Honaker, BSN, RN, CWOCN • Wound Ostomy Continence Coordinator • Baptist Health Lexington • Lexington, Kentucky Dorothy Brockopp, PhD, RN • Evidence-Based Practice Consultant • Baptist Health Lexington • Lexington, Kentucky Krista Moe, PhD • Evidence-Based Practice Consultant • Baptist Health Lexington • Lexington, Kentucky.AbstractPURPOSE: To enhance the learner's competence with knowledge of the results of research examining suspected deep tissue injury profiles.
Advances in skin & wound care.Adv Skin Wound Care.2014 Mar;27(3):133-40. doi: 10.1097/01.ASW.0000443267.25288.87.
PURPOSE: To enhance the learner's competence with knowledge of the results of research examining suspected deep tissue injury profiles.TARGET AUDIENCE: This continuing education activity is intended for physicians and nurses with an interest in skin and wound care.OBJECTIVES: After participating in
PMID 24531520

Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: a randomized controlled trial.

Joutsiniemi T, Timonen S, Leino R, Palo P, Ekblad U.Author information Department of Obstetrics and Gynecology, Turku University Central Hospital, Kiinamyllynkatu 4-8, 20520, Turku, Finland, titta.joutsiniemi@tyks.fi.AbstractPURPOSE: To test the efficacy and safety of ursodeoxycholic acid (UDCA) in the treatment of patients with intrahepatic cholestasis of pregnancy (ICP).
Archives of gynecology and obstetrics.Arch Gynecol Obstet.2014 Mar;289(3):541-7. doi: 10.1007/s00404-013-2995-5. Epub 2013 Aug 27.
PURPOSE: To test the efficacy and safety of ursodeoxycholic acid (UDCA) in the treatment of patients with intrahepatic cholestasis of pregnancy (ICP).METHODS: In the randomized (double-blind, placebo-controlled) study 20 pregnant women with ICP received (random allocation of) either 450 mg/day UDCA
PMID 23978872

Limits of agreement between measures obtained from standard laboratory and the point-of-care device Hemochron Signature Elite(R) during acute haemorrhage.

Gauss T, Hamada S, Jurcisin I, Dahmani S, Boudaoud L, Mantz J, Paugam-Burtz C.Author information Department of Anaesthesia and Critical Care and.AbstractBACKGROUND: /st> Rapid diagnosis of coagulopathy in the bleeding patient using point-of-care (POC) devices would be ideal. The Hemochron Signature Elite(®) (HC(®)) is a POC device that determines international normalized ratio (INR) and activated partial thromboplastin time (aPTT). The aim of the study was to evaluate the agreement for INR and aPTT between the HC(®) and standard laboratory values in acute haemorrhage.
British journal of anaesthesia.Br J Anaesth.2014 Mar;112(3):514-20. doi: 10.1093/bja/aet384. Epub 2013 Dec 12.
BACKGROUND: /st> Rapid diagnosis of coagulopathy in the bleeding patient using point-of-care (POC) devices would be ideal. The Hemochron Signature Elite(®) (HC(®)) is a POC device that determines international normalized ratio (INR) and activated partial thromboplastin time (aPTT). The aim of t
PMID 24335551

Shiraishi Takuya,Kadono Shojiro,Haramura Masayuki,Kodama Hirofumi,Ono Yoshiyuki,Iikura Hitoshi,Esaki Tohru,Koga Takaki,Hattori Kunihiro,Watanabe Yoshiaki,Sakamoto Akihisa,Yoshihashi Kazutaka,Kitazawa Takehisa,Esaki Keiko,Ohta Masateru,Sato Haruhiko,Kozono Toshiro
CHEMICAL & PHARMACEUTICAL BULLETIN 58(1), 38-44, 2010
… Selective factor VIIa-tissue factor complex (FVIIa/TF) inhibition is regarded as a promising target for developing new anticoagulant drugs. … In previous reports, we described a S3 subsite found in the X-ray crystal structure of compound 2 that bound to FVIIa/soluble tissue factor (sTF). …
NAID 130000140762

Effects of Heparin and Its 6-O-and 2-O-Desulfated Derivatives with Low Anticoagulant Activity on Proliferation of Human Neural Stem/Progenitor Cells(CELL AND TISSUE ENGINEERING, <Special Issue>Advances in Biomedical Science and Engineering)

Mori Hideki,Kanemura Yonehiro,Onaya Junichi,Hara Masayuki,Miyake Jun,Yamasaki Mami,Kariya Yutaka
Journal of bioscience and bioengineering 100(1), 54-61, 2005-07-25
… 6-DSH showed lower anticoagulant activity than intact heparin or 2-DSH, as measured by the activated partial thromboplastin time and thrombin time. …
NAID 110002703743

リンク元	「血液凝固因子」「組織トロンボプラスチン」
関連記事	「thromboplastin」

英: coagulation factor (Z), clotting factor, blood coagulation factor, blood coagulation factors
関: ビタミンK

15種類ある

凝固因子	慣用語・同義語	ビタミンK依存	血液中半減期(hr)	産生器官	染色体座乗部位
I	fibrinogen		100-150	肝臓	4q26
II	prothronbin	○	50-80	肝臓	11p141-q12
III	tissue thromboplastin			体の各組織	1pter-p21
IV	calcium ion			肝臓
V	labile factor/proaccelerin		24	肝臓	1q21-q25
VII	stable factor/proconvertin	○	6	肝臓	13q34
VIII	antihemophilic factor		12	細網系?	xq28
IX	Christmas factor	○	24	肝臓	xq26.3-q27.2
X	Stuart factor	○	25-60	肝臓	13q34
XI	plasma thromboplastin antecedent		40-80	肝臓	4q35
XII	Hageman factor		50-70	肝臓	5q33-qter
XIII	fibrin stabilizing factor		150	肝臓	6p24-p21.3
prekallikrein	Fletcher factor		35	肝臓	4q35
hight molecular weight kininogen	Fitzgerold factor		150	肝臓	3q26-qter
von Willebrand factor			24	血管内皮血小板糸球体	12pter-p12